Search

Ysios BioFund 3 (YBF 3) is the firm’s largest fund to date. To invest in up to 15 companies in Europe and the US, with eight investments already made alongside top US and European investors

Biotech companies are expanding their workforce amid the pandemic, accentuating in 2020 the growth trend of recent years, in which staff increased by 7.6% in 2019 and accounted for 12.8% of people

The conferences are: BioEquity Europe Digital, Foro Medcap BME 2021, Oxford Global’s Online Drug Discovery Week, Jefferies Virtual Healthcare Conference 2021, Precision in Drug Discovery & Preclinical

Asabys, who has been in business for almost 3 years, has considered sustainability as a fundamental pillar of its strategic objectives since inception

La compañía invierte 3,6 M€ en I+D sin impactos significativos derivados de la pandemia covid-19

3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications

Biotech company Cytoki Pharma (Copenhagen, Denmark) develops new proteins based on interleukin 22 (IL-22) for the treatment of epithelial lesions

Adcendo (Copenhagen, Denmark), is a biotechnology company specializing in the development of immunoconjugated drugs for the treatment of certain types of cancer that do not respond to current

In less than 12 months, the collaboration between Chemotargets, based in the Barcelona Science Park, and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of

This year saw over €150 million in private capital invested, compared to €103 million in 2019. Publicly traded biotech firms attracted over €70 million on capital markets, up 35% from 2019